Comparison of effect of NB-UVB with and without topical Latanoprost solution or placebo in Vitiligo Patients

Comparison of effect of NB-UVB with and without topical Latanoprost solution or placebo in Vitiligo Patients: a triple-blind clinical trial study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N283

Enrollment

Registered

2019-05-29

Start date

2019-06-22

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo. Vitiligo

Interventions

Intervention 1: Intervention group: NB-UVB radiation at a dose of 0.3 J/cm2 (wavelength from 311 to 313 nm) for a maximum of 3 minutes three times a week for three consecutive months with a Latanopros

Eligibility

Sex/Gender

All

Age

12 Years to 70 Years

Inclusion criteria

Inclusion criteria: Age of 12 to 70 years Vitiligo lesions with at least one lesions on each sides Involving at least 20% of the body surface

Exclusion criteria

Exclusion criteria: Malignant skin disease Failure of previous radiotherapy Pregnancy or breastfeeding Hepatic or renal disease Lupus Erythematosus Photosensitivity

Design outcomes

Primary

Measure	Time frame
Improvement of Vitiligo lesions. Timepoint: 3 months after the intervention. Method of measurement: With physical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Hanieh Karimi

Hamedan University of Medical Sciences

haniehkarimi67@gmail.com+98 81 3827 4184

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026